Protocol Ledger

NCT05629390 · Phase III · COMPLETED

Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study

Interventional Phase III clinical trial protocol NCT05629390 sponsored by LianBio in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-23 Enrollment: 163 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05629390
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)163 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05629390
Protocol FieldVerified Registry Value
NCT IdentifierNCT05629390
Consolidated Lead SponsorLianBio
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment163 participants (ACTUAL)
Registered Start Date2022-10-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI